Bactericidal Activity of Moxifloxacin on Exponential and Stationary Phase Cultures of Mycobacterium tuberculosis

REFERENCES

• Gillespie SH, Kennedy N. Fluoroquinolones: a new treat-ment for tuberculosis? Int J Tuber Lung Dis 1998; 2: 265–271.
   PubMed Web of Science ®Google Scholar
• Hu Y, Coates ARM, Mitchison DA. Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of My-cobacterium tuberculosis. Antimicrob Agents Chemother 2003; 47: 653–657.
   PubMed Web of Science ®Google Scholar
• www.tballiance . org.
   Google Scholar
• Nuermberger EL, Yoshimatsu T, Tyagi S, 'Brien RJO, Ver-non AN, Chaisson R E, et al. Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. Am J Res Crit Care Med 2004; 169: 421–426.
   Google Scholar
• Burman WJ, Goldberg S, Johnson JL, Muzanye G, Engle M, Mosher A. et al. Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Am J Res Crit Care Med 2006; 174: 331–338.
   PubMed Web of Science ®Google Scholar
• Conde MB, Efron A, Loredo C, Muzy-de-Souza G, Graça N, Cezar M., et al. A randomized, placebo-controlled trial of moxifloxacin vs. ethambutol in the initial phase of tuberculosis therapy in Brazil. Abstract 736-aLB. 47th Inter science Confe-rence of Antimicrobial. Agents and Chemotherapy, Chicago, IL, 2007; September 19.
   Google Scholar
• Rustomjee R, Lienhardt C, Kanyok T, Davies GR, Levin J, Mthiyane T, et al. A phase II study of the sterilizing activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculo-sis. Int J Tuber Lung Dis 2008; 12: 128–138.
   PubMed Web of Science ®Google Scholar
• Nuermberger EL, Yoshimatsu T, Tyagi S, Williams K, Rosenthal I, O'Brien RJ, et al. Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis. Am J Res Crit Care Med 2004; 170: 1131–1134.
   PubMed Web of Science ®Google Scholar
• Nuermberger EL, Yoshimatsu T, Tyagi S, O'Brien, R.J, Vernon AN, Chaisson R E, et al. Moxifloxacin-containing regi-men greatly reduces time to culture conversion in murine tuber-culosis. Am J Res Crit Care Med 2004; 169: 421–426.
   PubMed Web of Science ®Google Scholar
• Kubendiran G, Paramasivan CN, Sulochana S, Mitchison DA. Moxifloxacin and gatifloxacin in an acid model of persistent Mycobacterium tuberculosis. J Chemother 2006; 18: 617–623.
   PubMed Web of Science ®Google Scholar
• Herbert D, Paramasivan CN, Venkatesan P, Kubendiran G, Prabhakar R, Mitchison DA. Bactericidal action of ofloxacin, sulbactam-ampicillin, rifampin, and isoniazid on logarithmic- and stationary-phase cultures of Mycobacterium tuberculosis. Anti-microb Agents Chemother 1996; 40: 2296–2299.
   PubMed Web of Science ®Google Scholar
• Paramasivan CN, Sulochana S, Kubendiran G, Venkate-san P, Mitchison, DA. Bactericidal action of gatifloxacin, ri-fampin, and isoniazid on logarithmic- and stationary-phase cultures of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2005; 49: 627–631.
   PubMed Web of Science ®Google Scholar
• Garton NJ, Waddell SJ, Sherratt AL, Lee SM, Smith RJ, Senner C, et al. Cytological and transcript analyses reveal fat an-dlLazy persister-like bacilli in tuberculous sputum. Plos Med. 2008; In press.
   Google Scholar
• Park HD, Guinn KM, Harrell MI, Liao R, Voskui I MI, Tompa M, et al. Ry3133c/dosR is a transcription factor that mediates the hypoxic response of Mycobacterium tuberculosis. Mol Microb 2003; 48, 833–843.
   PubMed Web of Science ®Google Scholar
• Stass H, Kubitza D, Halabi A, Delesen H. Pharmacokine-tics of moxifloxacin, a novel 8- methoxy — quinolone, in patients with renal dysfunction. Br J Clin Pharm. 2002; 53: 232–237.
   PubMed Web of Science ®Google Scholar
• Gosling RD, Ulso LO, Sam NE, Bongard E, Kanduma EG, Nyindo M, et al. The bactericidal activity of moxifloxacin in Patients with pulmonary tuberculosis. Am J Res Crit Care Med 2003; 168: 1342–1345.
   PubMed Web of Science ®Google Scholar
• Pletz, M. Roux WRA, Roth de A, Neumann K-H, Mauch, H, Lode H. Early bactericidal activity of moxifloxacin in treat-ment of pulmonary tuberculosis: a prospective, randomized study. Antimicrob Agents Chemother 2004; 48: 780–782.
   Google Scholar
• Nuermberger E, Tyagi S, Tasneen R, Williams KN, Almeida D, Rosenthal I., et al. Powerful bactericidal and steriliz-ing activity of a regimen containing PA-824, moxifloxacin and pyrazinamide in the murine model of tuberculosis. Antimicrob Agents Chemother 2008; Feb 19: [Epub ahead of print].
   Google Scholar
• Rosenthal I.M, Williams K, Tyagi S, Vernon AA, Peloquin CA, Bishai WR, et al. Weekly moxifloxacin and rifapentine is more active than the denver regimen in murine tuberculosis. Am J Res Crit Care Med 2005; 172: 1457–1462.
   Google Scholar
• Rosenthal IM, Williams K, Tyagi S, Peloquin CA, Vernon AA, Bishai WR, et al. Potent twice-weekly rifapentine-containing regimens in murine tuberculosis. Am J Res Crit Care Med. 2006; 174: 94–101.
   PubMed Web of Science ®Google Scholar
• Rosenthal IM, Zhang M, Williams KN, Peloquin CA, Tyagi S, Vernon AA, et al Daily dosing of rifapentine cures tubercu-losis in three months or less in the murine model. PLoS Med 2007; 4: e344.
   PubMed Web of Science ®Google Scholar
• Dorman S, Johnson J, Padayatchi N, Goldberg S, Boze-man L, Chaisson R Moxifloxacin vs. isoniazid in the first 2 months of treatment for pulmonary tuberculosis, Abstract L-736b. 47th Intersci. Conf. Antimicrobial Agents and Chemother-apy. Chicago, IL, 2007; September 19.
   Google Scholar
• Carole DM, Sonya SS, Kwonjune JS, Michael LR, Sidney SA, et al. Comprehensive treatment extensively drug resistant tu-berculosis. N Engl J Med; 359: 6, 563 — 564.
   Google Scholar